4/15
11:05 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $90.00 to $100.00. They now have a "buy" rating on the stock.
4/12
08:14 am
ntra
Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
Low
Report
Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
4/11
08:14 am
ntra
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation [Yahoo! Finance]
Low
Report
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation [Yahoo! Finance]
4/11
08:00 am
ntra
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Low
Report
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
4/10
05:41 pm
ntra
FBT: An Equal Weight Way To Play Biotech [Seeking Alpha]
Low
Report
FBT: An Equal Weight Way To Play Biotech [Seeking Alpha]
4/8
10:06 am
ntra
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $117.00 price target on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $117.00 price target on the stock.
4/8
08:14 am
ntra
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients [Yahoo! Finance]
Medium
Report
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients [Yahoo! Finance]
4/8
08:00 am
ntra
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
Medium
Report
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
4/5
08:22 am
ntra
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. They now have a $120.00 price target on the stock.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. They now have a $120.00 price target on the stock.
4/5
07:14 am
ntra
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer [Yahoo! Finance]
Medium
Report
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer [Yahoo! Finance]
4/5
07:00 am
ntra
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Medium
Report
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
4/1
08:19 am
ntra
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer [Yahoo! Finance]
Low
Report
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer [Yahoo! Finance]
4/1
08:00 am
ntra
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Low
Report
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
3/22
03:29 pm
ntra
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine [Seeking Alpha]
Low
Report
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine [Seeking Alpha]
3/20
06:01 am
ntra
Will Natera (NTRA) Continue to Deliver Solid Topline Growth? [Yahoo! Finance]
Low
Report
Will Natera (NTRA) Continue to Deliver Solid Topline Growth? [Yahoo! Finance]
3/18
07:09 am
ntra
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer [Yahoo! Finance]
Low
Report
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer [Yahoo! Finance]
3/18
07:00 am
ntra
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Low
Report
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
3/14
08:12 am
ntra
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease [Yahoo! Finance]
Low
Report
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease [Yahoo! Finance]
3/14
08:00 am
ntra
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
Low
Report
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
3/14
02:03 am
ntra
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/12
08:31 am
ntra
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers [Yahoo! Finance]
Low
Report
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers [Yahoo! Finance]
3/12
08:00 am
ntra
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
Low
Report
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
3/8
01:42 am
ntra
SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA) [Yahoo! Finance]
Low
Report
SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA) [Yahoo! Finance]
3/7
08:08 am
ntra
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan [Yahoo! Finance]
Low
Report
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan [Yahoo! Finance]
3/7
08:00 am
ntra
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
Low
Report
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan